Search

Your search keyword '"Tulchinsky, Mark"' showing total 363 results
Start Over Author "Tulchinsky, Mark"
363 results on '"Tulchinsky, Mark"'

5. Assessing potential impact of 2015 American Thyroid Association guidelines on community standard practice for I-131 treatment of low-risk differentiated thyroid cancer: case study of Jordan

Author

Juweid, Malik E., Rabadi, Nidal J., Tulchinsky, Mark, Aloqaily, Mohammed, Al-Momani, Ahmad, Arabiat, Majd, Abu Ain, Gassem, Al Hawari, Hussam, Al-Momani, Munther, Mismar, Ayman, Abulaban, Amr, Taha, Ibrahim, Alhouri, Abdullah, Zayed, Ayman, Albsoul, Nader, and Al-Abbadi, Mousa A.

Published
2021
Full Text
View/download PDF

24. SNMMI Procedure Standard/EANM Practice Guideline for Nuclear Medicine Evaluation and Therapy of Differentiated Thyroid Cancer: Abbreviated Version

Author

Avram, Anca M, Giovanella, Luca, Greenspan, Bennett, Lawson, Susan A, Luster, Markus, Nostrand, Douglas Van, Peacock, Justin G, Petranović Ovčariček, Petra, Silberstein, Edward, Tulchinsky, Mark, Verburg, Frederik A, Vrachimis, Alexis, and Radiology & Nuclear Medicine

Subjects
differentiated thyroid cancer, guideline, SDG 3 - Good Health and Well-being
Abstract

Differentiated thyroid cancers (DTC) are slow- growing tumors with very low disease-specific mortality rates for local−regional disease (5-y survival: 99.9% for localized disease, 98.3% for regional metastatic disease). However, distant metastatic disease is associated with significantly worse prognosis (5-y survival: 54.9%) (1). Standard-of-care management for DTC includes risk-adapted surgery, postoperative 131I therapy, and thyroid hormone therapy. In uncommon cases of radioiodine-refractory tumors, additional therapy may include reoperative surgical intervention, external radiotherapy, and interventional radiology for treatment of locoregional metastases and multikinase or tyrosine kinase inhibitors for treatment of distant metastatic disease.

Published
2022

26. Comprehensive Analysis of Key Proteins Involved in Radioresistance of Prostate Cancer by Integrating Protein-protein Interaction Networks

Author

Li Dujian, Németh Balázs, Gyöngyi Zoltán, Karádi Kázmér, Wang Xiaoxia, Memarpour Mahtab, Rasool Nouman, Hegyi Péter, Marta Katalin, Révész Péter, Tóth Barbara, Luan Yun, Taghvamanesh Sara, Tulchinsky Mark, Slonimsky Einat, Sang-Ngoen Thanyaporn, Qian Duocheng, Varga Gábor, Shao Jia, Liu Dongsen, Naseer Sheraz, M. Czumbel László, Shahbaz Umar, Li Quan, H. Morowvat Mohammad, Liu Xiaoli, Mátrai Péter, Sui Shujian, Gerber Gábor, Li Yinuo, Sun Yongchao, Gao Qi, Zhang Shanshan, Karami Forough, Su Hao, Zhu Yansong, Xu Chaoyue, Hussain Waqar, Karami Somayeh, Sadaeng Wuttapon, Szanyi István, Rafiee Azade, Zhang Zhaohua, and Daanial Khan Yaser

Subjects
Computational Mathematics, Prostate cancer, Radioresistance, Genetics, medicine, Key (cryptography), Computational biology, Biology, medicine.disease, Molecular Biology, Biochemistry, Protein protein interaction network
Abstract

Background: Radioresistance remains a significant obstacle in the treatment of prostate cancer (PCa). The mechanisms underlying the radioresistance in PCa remained to be further investigated. Methods: GSE53902 dataset was used in this study to identify radioresistance-related mRNAs. Protein-protein interaction (PPI) network was constructed based on STRING analysis. DAVID system was used to predict the potential roles of radioresistance-related mRNAs. Results: We screened and re-annotated the GSE53902 dataset to identify radioresistance-related mRNAs. A total of 445 up-regulated and 1036 down-regulated mRNAs were identified in radioresistance PCa cells. Three key PPI networks consisting of 81 proteins were further constructed in PCa. Bioinformatics analysis revealed that these genes were involved in regulating MAP kinase activity, response to hypoxia, regulation of the apoptotic process, mitotic nuclear division, and regulation of mRNA stability. Moreover, we observed that radioresistance-related mRNAs, such as PRC1, RAD54L, PIK3R3, ASB2, FBXO32, LPAR1, RNF14, and UBA7, were dysregulated and correlated to the survival time in PCa. Conclusion: We thought this study would be useful to understand the mechanisms underlying radioresistance of PCa and identify novel prognostic markers for PCa.

Published
2021

27. SNMMI Procedure Standard/EANM Practice Guideline for Nuclear Medicine Evaluation and Therapy of Differentiated Thyroid Cancer:Abbreviated Version

Author

Avram, Anca M., Giovanella, Luca, Greenspan, Bennett, Lawson, Susan A., Luster, Markus, Van Nostrand, Douglas, Peacock, Justin G., Ovčariček, Petra Petranović, Silberstein, Edward, Tulchinsky, Mark, Verburg, Frederik A., Vrachimis, Alexis, Avram, Anca M., Giovanella, Luca, Greenspan, Bennett, Lawson, Susan A., Luster, Markus, Van Nostrand, Douglas, Peacock, Justin G., Ovčariček, Petra Petranović, Silberstein, Edward, Tulchinsky, Mark, Verburg, Frederik A., and Vrachimis, Alexis

Published
2022

40. Appropriate Use Criteria for Nuclear Medicine in the Evaluation and Treatment of Differentiated Thyroid Cancer

Author

Donohoe, Kevin J., primary, Aloff, Jennifer, additional, Avram, Anca M., additional, Bennet, K.G., additional, Giovanella, Luca, additional, Greenspan, Bennett, additional, Gulec, Seza, additional, Hassan, Aamna, additional, Kloos, Richard T., additional, Solórzano, Carmen C., additional, Stack, Brendan C., additional, Tulchinsky, Mark, additional, Tuttle, Robert Michael, additional, Van Nostrand, Douglas, additional, and Wexler, Jason A., additional

Published
2020
Full Text
View/download PDF

44. The role of Tg kinetics in predicting 2-[18F]-FDG PET/CT results and overall survival in patients affected by differentiated thyroid carcinoma with detectable Tg and negative 131I-scan.

Author

Albano, Domenico, Tulchinsky, Mark, Dondi, Francesco, Mazzoletti, Angelica, Bertagna, Francesco, and Giubbini, Raffaele

Abstract

Purpose: The aim of this study was to assess the potential role of thyroglobulin (Tg) kinetics in predicting 2-[18F]-FDG-PET/CT results and overall survival (OS) in patients affected by differentiated thyroid carcinoma (DTC) and suspected recurrence. Methods: On hundred and thirty-nine patients were retrospectively included. All patients underwent 2-[18F]-FDG-PET/CT due to detectable Tg levels and negative [131I] whole-body scan. The last two consecutive serum Tg measurements before PET/CT were used for Tg-doubling time (TgDT) and Tg-velocity (Tg-vel) calculation. Receiver operating characteristic (ROC) curves were used to determine the optimal cutoff points for Tg, TgDT and Tg-vel for predicting PET/CT results. Results: One hundred and fifteen (83%) patients had positive PET/CT for DTC recurrence, while the remaining 24 (17%) negative. Stimulated Tg before PET and Tg-vel were significantly higher in patients with a positive PET/CT scan than negative scan (average Tg 190 vs 14 ng/mL, p = 0.006; average Tg-vel 4.2 vs 1.7 ng/mL/y, p < 0.001). Instead, TgDT was significantly shorter in positive scan (average TgDT 1.4 vs 4.4 years, p < 0.001). ROC curve analysis revealed the best Tg, TgDT and Tg-vel cutoff of 18 ng/mL,1.36 years and 1.95 ng/mL/y. In patients with Tg<18 ng/mL, the PET/CT detection rate was significantly lower in patients with low Tg-vel (p = 0.018) and with long TgDT (p = 0.001). ATA class risk, PET/CT results and Tg before PET were confirmed to be independent prognostic variables for OS. Conclusions: Tg kinetics may help to predict 2-[18F]-FDG-PET/CT results in DTC patients with negative [131I]WBS and detectable Tg, especially in case of low-moderate Tg. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results